New guidelines about latent tuberculosis infection in children and adolescents: a welcome advancement.
Nelson
Lisa J
LJ
Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS E-10, Atlanta, GA 30333, USA. lnelson@cdc.gov
Jereb
John A
JA
Castro
Kenneth G
KG
D000293:Adolescent; D000995:Antitubercular Agents / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D009169:Mycobacterium tuberculosis / Q000502:physiology; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014374:Tuberculin Test; D014376:Tuberculosis / Q000175:diagnosis* / Q000517:prevention & control*; D017735:Virus Latency
D000995:Antitubercular Agents; D007538:Isoniazid